Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Arch Pathol Lab Med. 2012 Dec;136(12):1515-21. doi: 10.5858/arpa.2012-0042-OA.
Frozen sections can help determine the extent of surgery by distinguishing in situ, minimally invasive, and invasive adenocarcinoma of the lung.
To evaluate our experience with the frozen section diagnosis of these lesions using root-cause analysis.
Frozen sections from 224 consecutive primary pulmonary adenocarcinomas (in situ, 27 [12.1%]; minimally invasive, 46 [20.5%]; invasive, 151 [67.4%]) were reviewed. Features that could have contributed to frozen section errors and deferrals were evaluated.
There were no false-positive diagnoses of malignancy. Frozen section errors and deferrals were identified in 12.1% (27 of 224) and 6.3% (14 of 224) of the cases, respectively. Significantly more errors occurred in the diagnosis of in situ and minimally invasive adenocarcinoma than in the diagnosis of invasive adenocarcinoma (P < .001). Frozen section errors and deferrals were twice as frequent in lesions smaller than 1.0 cm (P = .09). Features significantly associated with errors and deferrals included intraoperative consultation by more than one pathologist (P = .003) and more than one sample of frozen lung section (P = .001). Inflammation with reactive atypia, fibrosis/scar, sampling problems, and suboptimal quality sections were identified in 51.2% (21 of 41), 36.6% (15 of 41), 26.8% (11 of 41), and 9.8% (4 of 41) of the errors and deferrals, respectively (more than one of these factors was identified in some cases). Frozen section errors and deferrals had significant clinical impact in only 4 patients (1.8%); each had to undergo completion video-assisted thoracoscopic lobectomy less than 90 days after the initial surgery.
The distinction of in situ from minimally invasive adenocarcinoma is difficult in both frozen and permanent sections. We identified several technical and interpretive features that likely contributed to frozen section errors and deferrals and suggest practice modifications that are likely to improve diagnostic accuracy.
冰冻切片有助于通过区分原位、微创和浸润性肺腺癌来确定手术范围。
使用根本原因分析评估我们使用冰冻切片诊断这些病变的经验。
回顾了 224 例连续原发性肺腺癌(原位 27 例[12.1%];微创 46 例[20.5%];浸润性 151 例[67.4%])的冰冻切片。评估了可能导致冰冻切片错误和延迟的特征。
没有恶性肿瘤的假阳性诊断。在 12.1%(27/224)和 6.3%(14/224)的病例中分别发现了冰冻切片错误和延迟。原位和微创腺癌的诊断错误和延迟明显多于浸润性腺癌(P<0.001)。在小于 1.0cm 的病变中,冰冻切片错误和延迟的频率增加了一倍(P=0.09)。与错误和延迟显著相关的特征包括由一名以上病理学家进行术中咨询(P=0.003)和对多个冰冻肺切片样本进行检测(P=0.001)。在 51.2%(21/41)、36.6%(15/41)、26.8%(11/41)和 9.8%(4/41)的错误和延迟中分别发现了炎症伴反应性非典型性、纤维化/瘢痕、采样问题和切片质量差(在一些病例中存在多种这些因素)。只有 4 名患者(1.8%)的冰冻切片错误和延迟对临床有显著影响;这 4 名患者均在初次手术后不到 90 天接受了全胸腔镜肺叶切除术。
原位和微创腺癌在冰冻切片和永久切片中都难以区分。我们确定了一些可能导致冰冻切片错误和延迟的技术和解释特征,并提出了可能提高诊断准确性的实践修改建议。